More tools:
Markets
·
Screener
·
Research
·
Chat
Kailera Therapeutics, Inc. Common Stock (KLRA) Financial Statements
Kailera Therapeutics, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG01Q3NQQK9
XNAS · usd
16.43
▲ 0.20 (1.23%)
As of 2026-09-08
1M
6M
1Y
Valuation
Market Cap
$2.1B
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
16.23
Day's Range
15.62 – 16.63
52-Week Range
15.15 – 28.23
Volume
1.0M
Avg Volume
631.5K
Share Statistics
Shares Outstanding
129.6M
Employees
—
Exchange
XNAS
Listed
2026-04-17
Share count as of August 6, 2026
View
Income Statement
Balance Sheet
Cash Flow
Key Metrics
Valuation
Comparable Companies
Notes & Facts
DCF Model
Earnings Calls
Guidance
Presentations
Detail
Standard
Detailed
Period
Annual
Quarterly
TTM
Loading Income Statement…
Key questions about Kailera Therapeutics, Inc. Common Stock (KLRA)
What is Kailera Therapeutics, Inc. Common Stock's Market Cap?
Kailera Therapeutics, Inc. Common Stock's Market Cap is $2.1B, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Subscribe
Income Statement
(in thousands of USD, except per-share data)
Source: Akyla.ai
Line Item
Jun 30, 2026
Mar 31, 2026
Jun 30, 2025
Mar 31, 2025
Operating expenses
Research and development
101,061.0
70,873.0
General and administrative
20,312.0
13,787.0
Total operating expenses
121,373.0
84,660.0
Loss from operations
(121,373.0)
(84,660.0)
Interest income
9,994.0
5,716.0
Other income (expense), net
72.0
—
Total other income
10,066.0
5,795.0
Net loss
(111,307.0)
(78,865.0)
Net loss per share attributable to common stockholders - basic
(1.09)
(3,650.00)
Net loss per share attributable to common stockholders - diluted
(1.09)
(3,650.00)